Association of osteopontin expression with the prognosis of glioma patient: a meta-analysis

Tumor Biology

Volumn 36, Issue 1, 2015, Pages 429-436

  Zhao, Mingfei ^a   Xu, Hangdi ^b   Liang, Feng ^a   He, Jiliang ^a   Zhang, Jianmin ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Glioma; Meta analysis; Osteopontin; Prognosis

Indexed keywords

MESSENGER RNA; OSTEOPONTIN; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SURVIVAL RATE; TUMOR VOLUME; BRAIN TUMOR; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL;

BRAIN NEOPLASMS; GLIOMA; HUMANS; OSTEOPONTIN; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84925493667     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2645-y     Document Type: Article

References (24)

1. Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, Vrinda M, et al. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev. 2010;19:1409–22.
2. Tsai WC, Lee HS, Lin CK, Chen A, Nieh S, Ma HI. The association of osteopontin and LMX1A expression with World Health Organization grade in meningiomas and gliomas. Histopathology. 2012;61:844–56.
3. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen JY. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res. 2007;67:2089–97.
4. Lu DY, Yeh WL, Huang SM, Tang CH, Lin HY, Chou SJ. Osteopontin increases heme oxygenase-1 expression and subsequently induces cell migration and invasion in glioma cells. Neuro Oncol. 2012;14:1367–78.
5. Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, Bosch KS, et al. Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma. Immunology. 2011;132:39–48.
6. Cheng J, Wang W, Sun C, Li M, Wang B, Lv Y. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol. 2014;48(9):806–14.
7. Rud AK, Boye K, Oijordsbakken M, Lund-Iversen M, Halvorsen AR, Solberg SK. Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer. 2013;13:540.
8. Cao DX, Li ZJ, Jiang XO, Lum YL, Khin E, Lee NP, et al. Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol. 2012;18:3923–30.
9. Kumar S, Sharma P, Kumar D, Chakraborty G, Gorain M, Kundu GC. Functional characterization of stromal osteopontin in melanoma progression and metastasis. PLoS One. 2013;8:e69116.
10. Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer. 2000;82:1967–73.
11. Ding Q, Stewart Jr J, Prince CW, Chang PL, Trikha M, Han X, et al. Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res. 2002;62:5336–43.
12. He ZQ, Yin L, Zhao HY. Expression and significance of osteopontin and integrin β3 in human gliomas. CMINS. 2005;10:508–11.
13. Sun CY, Bu XY. Expression and significance of osteopontin in human gliomas. J Fourth Mil Med Univ. 2005;26:1677–9.
14. Yu WH, Chen F, Che ZH. Preliminary study on expression of osteopontin in human gliomas. J Med Res. 2006;35:17–9.
15. Cheng BC, Wan JH, Feng CG, Li CY. Expressions of osteopontin and vascular endothelial growth factor in brain glioma and their association with the prognosis. Chin J Neuromed. 2006;5:22–6.
16. Yue YY, Yi HQ. Expressions of osteopontin in patients with gliomas. J Pract Diag Treat. 2006;20:516–7.
17. Zeng T, Lin YF, Yang WZ. Expression of osteopontin in human brain gliomas and its clinical meanings. Chin J Clin Neurosurg. 2007;12:162–4.
18. Said HM, Hagemann C, Staab A, Stojic J, Kühnel S, Vince GH, et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol. 2007;83:398–405.
19. Matusan-Ilijas K, Behrem S, Jonjic N, Zarkovic K, Lucin K. Osteopontin expression correlates with angiogenesis and survival in malignant astrocytoma. Pathol Oncol Res. 2008;14:293–8.
20. Du Q, Yu WH, Dong XQ. Expression of OPN and MMP-9 in human glioma in relation with its clinical significance. Zhejiang Med J. 2009;31:729–31.
21. Jiao BH. Expression and significance of OPN, MMP-9 and MVD in brain glioma. Master’s thesis. 2009;1–64.
22. Wang Y, Chen YH, Liu ZH, Wang RY, Jiao BH. Expression of MMP-9 and OPN in human glioma and their significance in the pathogenesis. J Brain Nerv Dis. 2012;20:128–32.
23. Erpolat OP, Gocun PU, Akmansu M, Ozgun G, Akyol G. Strahlenther O. Hypoxia-related molecules HIF-1α, CA9, and osteopontin: predictors of survival in patients with high-grade glioma. Strahlenther Onkol. 2013;189:147–54.
24. Papworth K, Bergh A, Grankvist K, Ljungberg B, Sandlund J, Rasmuson T. Osteopontin but not parathyroid hormone-related protein predicts prognosis in human renal cell carcinoma. Acta Oncol. 2013;52:159–65.